GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Teladoc Health Inc (NYSE:TDOC) » Definitions » Beneish M-Score
中文

Teladoc Health (Teladoc Health) Beneish M-Score : -3.10 (As of Apr. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Teladoc Health Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.1 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Teladoc Health's Beneish M-Score or its related term are showing as below:

TDOC' s Beneish M-Score Range Over the Past 10 Years
Min: -4.17   Med: -2.18   Max: -0.81
Current: -3.1

During the past 11 years, the highest Beneish M-Score of Teladoc Health was -0.81. The lowest was -4.17. And the median was -2.18.


Teladoc Health Beneish M-Score Historical Data

The historical data trend for Teladoc Health's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teladoc Health Beneish M-Score Chart

Teladoc Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.54 -0.81 -2.21 -4.17 -3.10

Teladoc Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.17 -3.53 -3.35 -3.40 -3.10

Competitive Comparison of Teladoc Health's Beneish M-Score

For the Health Information Services subindustry, Teladoc Health's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teladoc Health's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Teladoc Health's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Teladoc Health's Beneish M-Score falls into.



Teladoc Health Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Teladoc Health for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9029+0.528 * 0.9759+0.404 * 0.9467+0.892 * 1.0813+0.115 * 0.9534
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9723+4.679 * -0.122208-0.327 * 1.0039
=-3.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $230 Mil.
Revenue was 660.527 + 660.238 + 652.406 + 629.244 = $2,602 Mil.
Gross Profit was 467.103 + 474.278 + 461.866 + 439.137 = $1,842 Mil.
Total Current Assets was $1,489 Mil.
Total Assets was $4,392 Mil.
Property, Plant and Equipment(Net PPE) was $72 Mil.
Depreciation, Depletion and Amortization(DDA) was $351 Mil.
Selling, General, & Admin. Expense(SGA) was $1,367 Mil.
Total Current Liabilities was $421 Mil.
Long-Term Debt & Capital Lease Obligation was $1,582 Mil.
Net Income was -28.89 + -57.073 + -65.177 + -69.228 = $-220 Mil.
Non Operating Income was -3.624 + -8.027 + -12.817 + -9.139 = $-34 Mil.
Cash Flow from Operations was 130.082 + 105.601 + 101.182 + 13.156 = $350 Mil.
Total Receivables was $236 Mil.
Revenue was 637.709 + 611.402 + 592.379 + 565.35 = $2,407 Mil.
Gross Profit was 448.836 + 425.783 + 409.909 + 378.325 = $1,663 Mil.
Total Current Assets was $1,315 Mil.
Total Assets was $4,345 Mil.
Property, Plant and Equipment(Net PPE) was $71 Mil.
Depreciation, Depletion and Amortization(DDA) was $271 Mil.
Selling, General, & Admin. Expense(SGA) was $1,301 Mil.
Total Current Liabilities was $400 Mil.
Long-Term Debt & Capital Lease Obligation was $1,573 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(230.063 / 2602.415) / (235.645 / 2406.84)
=0.088404 / 0.097906
=0.9029

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1662.853 / 2406.84) / (1842.384 / 2602.415)
=0.690886 / 0.707952
=0.9759

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1489.048 + 72.092) / 4392.369) / (1 - (1315.388 + 71.472) / 4345.355)
=0.644579 / 0.680841
=0.9467

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2602.415 / 2406.84
=1.0813

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(270.643 / (270.643 + 71.472)) / (351.323 / (351.323 + 72.092))
=0.791088 / 0.829737
=0.9534

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1367.293 / 2602.415) / (1300.563 / 2406.84)
=0.525394 / 0.540361
=0.9723

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1581.525 + 420.616) / 4392.369) / ((1573.33 + 399.769) / 4345.355)
=0.455823 / 0.454071
=1.0039

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-220.368 - -33.607 - 350.021) / 4392.369
=-0.122208

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Teladoc Health has a M-score of -3.10 suggests that the company is unlikely to be a manipulator.


Teladoc Health Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Teladoc Health's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Teladoc Health (Teladoc Health) Business Description

Traded in Other Exchanges
Address
2 Manhattanville Road, Suite 203, Purchase, NY, USA, 10577
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
Executives
Daniel Trencher officer: SVP Corporate Strategy 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Vidya Raman-tangella officer: Chief Medical Officer 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Karen L Daniel director 2801 80TH STREET, KENOSHA WI 53141
Jason N Gorevic director, officer: President & CEO
Andrew Turitz officer: SVP - Business Development C/O TELADOC, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Stephany Verstraete officer: Chief Marketing Officer C/O TELADOC, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Adam C Vandervoort officer: Chief Legal Officer, Secretary 485 MADISON AVENUE, NEW YORK NY 10022
Mala Murthy officer: Chief Financial Officer C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Richard J Napolitano officer: Chief Accounting Officer MSCI INC., 7 WORLD TRADE CENTER, 250 GREENWICH STREET, 49TH FLOOR, NEW YORK NY 10007
Arnnon Geshuri officer: Chief Human Resources Officer 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Laizer Kornwasser officer: PRESIDENT, ENTERPRISE GROWTH 100 PARSONS POND DRIVE, FRANKLIN LAKES NJ 07417
Michael Willem Waters officer: CHIEF OPERATING OFFICER 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Jason Eric Evans director 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Claus Torp Jensen officer: Chief Innovation Officer 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Sandra L Fenwick director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577